These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27538585)

  • 61. Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ren S; Bermejo I; Simpson E; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Jul; 36(7):769-778. PubMed ID: 29502174
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapy.
    Meyer O; de Bandt M; Berthelot JM; Cantagrel A; Combe B; Fautrel B; Flipo RM; Lioté F; Maillefert JF; Saraux A; Wendling D; Guillemin F; Le Loët X;
    Joint Bone Spine; 2007 Jan; 74(1):73-8. PubMed ID: 17194614
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab.
    Klarenbeek NB; Güler-Yüksel M; van der Heijde DM; Hulsmans HM; Kerstens PJ; Molenaar TH; de Sonnaville PB; Huizinga TW; Dijkmans BA; Allaart CF
    Ann Rheum Dis; 2010 Dec; 69(12):2107-13. PubMed ID: 20610442
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Structural joint damage and hand bone loss in patients with rheumatoid arthritis.
    Ørnbjerg LM
    Dan Med J; 2018 Mar; 65(3):. PubMed ID: 29510810
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: a randomised double blind trial of sulphasalazine vs diclofenac sodium.
    Choy EH; Scott DL; Kingsley GH; Williams P; Wojtulewski J; Papasavvas G; Henderson E; Macfarlane D; Erhardt C; Young A; Plant MJ; Panayi GS
    Clin Exp Rheumatol; 2002; 20(3):351-8. PubMed ID: 12102471
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
    van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Anakinra for rheumatoid arthritis.
    Mertens M; Singh JA
    Cochrane Database Syst Rev; 2009 Jan; (1):CD005121. PubMed ID: 19160248
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.
    Tanaka Y; Takeuchi T; Amano K; Saito K; Hanami K; Nawata M; Fukuyo S; Kameda H; Kaneko Y; Kurasawa T; Nagasawa H; Hoshi D; Sato E; Yamanaka H
    Mod Rheumatol; 2014 May; 24(3):399-404. PubMed ID: 24252045
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivi des polyarthrites indifférenciées récentes (study and followup of early undifferentiated polyarthritis).
    Lukas C; Combe B; Ravaud P; Sibilia J; Landew R; van der Heijde D
    Arthritis Rheum; 2011 Jul; 63(7):1804-11. PubMed ID: 21452295
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis.
    Paulus HE; Di Primeo D; Sanda M; Lynch JM; Schwartz BA; Sharp JT; Genant HK; Weissman BN
    J Rheumatol; 2000 Jul; 27(7):1632-7. PubMed ID: 10914843
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Increased radiographic progression of distal hand osteoarthritis occurring during biologic DMARD monotherapy for concomitant rheumatoid arthritis.
    Lechtenboehmer CA; Burkard T; Reichenbach S; Walker UA; Burden AM; Hügle T
    Arthritis Res Ther; 2021 Oct; 23(1):267. PubMed ID: 34702319
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effects of glucocorticoids on radiological progression in rheumatoid arthritis.
    Kirwan JR; Bijlsma JW; Boers M; Shea BJ
    Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD006356. PubMed ID: 17253590
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry.
    Ornbjerg LM; Ostergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Ringsdal VS; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Dencker D; Hansen A; Andersen AR; Hetland ML
    Ann Rheum Dis; 2013 Jan; 72(1):57-63. PubMed ID: 22532636
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Disease progression and treatment responses in a prospective DMARD-naive seropositive early rheumatoid arthritis cohort: does gender matter?
    Jawaheer D; Maranian P; Park G; Lahiff M; Amjadi SS; Paulus HE
    J Rheumatol; 2010 Dec; 37(12):2475-85. PubMed ID: 20889597
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
    Dougados M; van der Heijde D; Chen YC; Greenwald M; Drescher E; Liu J; Beattie S; Witt S; de la Torre I; Gaich C; Rooney T; Schlichting D; de Bono S; Emery P
    Ann Rheum Dis; 2017 Jan; 76(1):88-95. PubMed ID: 27689735
    [TBL] [Abstract][Full Text] [Related]  

  • 76. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study.
    Peterfy C; Emery P; Tak PP; Østergaard M; DiCarlo J; Otsa K; Navarro Sarabia F; Pavelka K; Bagnard MA; Gylvin LH; Bernasconi C; Gabriele A
    Ann Rheum Dis; 2016 Jan; 75(1):170-7. PubMed ID: 25355728
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
    Pavelka K; Akkoç N; Al-Maini M; Zerbini CAF; Karateev DE; Nasonov EL; Rahman MU; Pedersen R; Dinh A; Shen Q; Vasilescu R; Kotak S; Mahgoub E; Vlahos B
    Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis.
    O'Mahony R; Richards A; Deighton C; Scott D
    Ann Rheum Dis; 2010 Oct; 69(10):1823-6. PubMed ID: 19224904
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.
    Nishimoto N; Hashimoto J; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Murata N; van der Heijde D; Kishimoto T
    Ann Rheum Dis; 2007 Sep; 66(9):1162-7. PubMed ID: 17485422
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses.
    Aletaha D; Smolen JS
    Rheumatology (Oxford); 2002 Dec; 41(12):1367-74. PubMed ID: 12468815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.